ProQR Therapeutics (NASDAQ:PRQR – Get Rating) has been assigned a consensus recommendation of “Hold” from the ten analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month […]
ProQR Therapeutics (NASDAQ: PRQR) has recently received a number of price target changes and ratings updates: 4/19/2022 – ProQR Therapeutics had its price target lowered by analysts at Cantor Fitzgerald from $6.00 to $3.50. 4/14/2022 – ProQR Therapeutics had its price target lowered by analysts at JMP Securities from $8.00 to $5.00. They now have […]
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of […]
Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Rating) have been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the […]
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 1,380,000 shares, a decrease of 31.7% from the February 28th total of 2,020,000 shares. Approximately 2.5% of the shares of the company are short sold. Based on an […]